Director John LaRocca filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 6, 2026, disclosing his initial beneficial ownership of securities in Elite Pharmaceuticals Inc /NV/ following a triggering event dated October 28, 2026.

Key Highlights

  • Reporting person: John LaRocca, identified as a Director of Elite Pharmaceuticals Inc /NV/
  • Triggering event date: October 28, 2026, the date of the event requiring the statement
  • Common stock held: 88,534 shares of Common Stock beneficially owned directly (Direct ownership)
  • No derivative securities: Table II discloses no derivative securities beneficially owned
  • Filing date: November 6, 2026, signed by John W LaRocca

LaRocca's Initial Beneficial Ownership Disclosure at Elite Pharmaceuticals

According to the filing, John LaRocca submitted a Form 3 Initial Statement of Beneficial Ownership, as required under Section 16(a) of the Securities Exchange Act of 1934. The issuer is identified as Elite Pharmaceuticals Inc /NV/, trading on OTC under the ticker symbol ELTP. LaRocca is listed solely in the capacity of Director, with the filing indicating it was made by one reporting person.

The filing discloses that LaRocca directly owns 88,534 shares of Common Stock, as reported in Table I. The ownership form is listed as Direct (D), with no indirect beneficial ownership arrangements noted. Table II, covering derivative securities such as puts, calls, warrants, options, or convertible securities, contains no entries, indicating that the filing reports no derivative holdings for LaRocca at the time of the triggering event.

The filing was signed by John W LaRocca on November 6, 2026, the same date it was submitted to the SEC. No amendments to a prior Form 3 are indicated, as the "If Amendment" field is left blank, confirming this is an original initial statement.

What Was Disclosed

John LaRocca, a Director at Elite Pharmaceuticals Inc /NV/ (OTC:ELTP), filed a Form 3 disclosing direct beneficial ownership of 88,534 shares of Common Stock as of the October 28, 2026 triggering event, with no derivative securities reported.